ROCKVILLE, Md., Jun 01, 2010 (BUSINESS WIRE) --Emergent BioSolutions Inc. (NYSE: EBS) announced today that the company
will be participating in the following investor conferences during June
- The Jefferies & Company 2010 Global Life Sciences Conference
June 8, 2010
11:00 AM Eastern
There will be a
full webcast with slides that will include discussion of the Company's
business activities, financial outlook and current news.
- The Needham & Company 9th Annual
New York, NY.
Corporate Overview Presentation
There will be a full webcast with slides that will
include discussion of the Company's business activities, financial
outlook and current news.
Both webcasts will be accessible from the Emergent website www.emergentbiosolutions.com
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company focused on the
development, manufacture and commercialization of vaccines and antibody
therapies that assist the body's immune system to prevent or treat
disease. Emergent's marketed product, BioThrax(R) (Anthrax
Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and
Drug Administration for the prevention of anthrax infection. Emergent's
product pipeline targets infectious diseases and includes programs
focused on anthrax, tuberculosis, typhoid, flu and chlamydia. Additional
information may be found at www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
Vice President, Corporate Communications